NIMACIMAB
UNII 85TS31SOL3

Substance Identification & Data

This profile provides standardized clinical and technical data for Nimacimab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 85TS31SOL3.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2098636-09-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

85TS31SOL3

CAS Registry Number

2098636-09-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

NIMACIMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C175163

National Cancer Institute reference terminology for clinical and research data.

INN ID

11023

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-02

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Nimacimab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

NIMACIMAB

Common Names & Synonyms

NIMACIMAB [INN]

NIMACIMAB [USAN]

Systematic Nomenclature

IMMUNOGLOBULIN G4 (228-PROLINE), ANTI-(HUMAN CANNABINOID RECEPTOR 1) (HUMAN-MUS MUSCULUS MONOCLONAL RYI-018 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RYI-018 .KAPPA.-CHAIN, DIMER

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS CANNABINOID RECEPTOR 1)HUMANIZED MONOCLONAL ANTIBODY: .GAMMA.4 HEAVY CHAIN (1-444) (HOMO SAPIENS VH (IGHV1-69*08 (88%) (IGHD)-IGHJ3*01 (91%)) (8.8.10) (1-107)-HOMO SAPIENS IGHG4*01 (HINGE(S10>P(225))) (108-444)) (131-215')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-215') (HOMO SAPIENS V-KAPPA ( IGKV3D-11*02 (90%) IGKJ1*01)(7.3.9) (1'-108')-HOMO SAPIENS IGKC*01 (109'-215')), DIMER (223-223'':226-226'')-BISDISULFIDE

SYS

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS CNR1 (CANNABINOID RECEPTOR 1, CANN6, CNR)), HUMANIZED MONOCLONAL ANTIBODYGAMMA4 HEAVY CHAIN HUMANIZED (1-444) (VH (HOMO SAPIENS IGHV1-69*02 (86.7%)-(IGHD)-IGHJ4*01 (90.9%)) (8.8.10) (1-117)-HOMO SAPIENS IGHG4*01 (CH1 (118-215), HINGE S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)), (131-215')-DISULFIDE WITH KAPPA LIGHT CHAIN HUMANIZED (1'-215') (VKAPPA (HOMO SAPIENS IGKV3D-11*02 (90.1%)-IGKJ1*01 (100%)) (7.3.9) (1'-108')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (204), V101 (192) (109'-215'))DIMER (223-223'':226-226'')-BISDISULFIDE

SYS